In contrast to CDKi, Bortezomib primarily affects the homologous repair system itself, resulting in synthetic lethality in CCNE1-amplified cancer cells: a genome-wide shRNA screen in 102 cancer cell lines revealed that BRCA1 was specifically required in CCNE1-amplified cell lines. The gene discussed is BRCA1; the disease is cancer.